Q-VANT Santiago Facility Earns EXCiPACT GMP Certification

Q-VANT Biosciences’ manufacturing facility in Santiago, Chile, has achieved EXCiPACT certification for pharmaceutical excipients, covering Q-VANT’s commercial-scale production of QS-21 and other high-purity saponin fractions for human and veterinary vaccines.

This milestone confirms that Q-VANT’s manufacturing operations and quality systems meet internationally recognized GMP requirements and strengthens the company’s ability to serve vaccine manufacturers, formulation partners and global health organizations with reliable, scalable supplies of critical adjuvant materials. As a vertically integrated company, Q-VANT manages the value chain from sustainable Quillaja biomass sourcing and processing through purification and commercial manufacturing at origin, with capacity to support billions of vaccine doses per year.

“GMP certification is a major milestone for Q-VANT and for the broader vaccine ecosystem,” said Juan Jose Albarran, CEO of Q-VANT Biosciences. “Our vertically integrated model gives vaccine developers the quality, scale and supply security required to advance human and veterinary vaccine programs worldwide.”

The Santiago facility provides a geographically diversified source of saponin adjuvants and offers a supply-chain advantage for vaccine development and global health initiatives.